Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management ... with three of Lilly's insulin products, including Humalog and Lyumjev ...

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after ... by the Medicines and Healthcare products Regulatory Agency (MHRA) last ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

INDIANAPOLIS -- Eli Lilly dialed back its 2024 forecast after underwhelming ... Company shares slipped in trading after the ...

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year over year to $3.1 billion. Sales for Zepbound, which ...

Eli Lilly LLY will report its ... of its FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound, helped Lilly deliver exceptionally strong results in the ...

Shares of Eli Lilly (NYSE ... full-year non-GAAP EPS of $16.10 to $16.60. What's behind Lilly's disappointing Q3 update? Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained ...